Endoleaks after endovascular repair of complex aortic aneurysms: always reintervene or monitor with CTA?

Endovascular repair of thoracoabdominal aneurysms requiring sealing above the renal arteries, with preservation of visceral vessels using fenestrated and/or branched devices (F/B-EVAR), has become a valid alternative to open surgery. However, endoleak remains a frequent complication and a potential driver of aneurysm sac growth. In this context, the study evaluated whether, in the absence of sac growth, a structured surveillance strategy with computed tomography angiography (CTA) could avoid unnecessary reinterventions.

Study characteristics

SAFE-AAA: ¿Son seguros los dispositivos Endologix en aneurisma de aorta abdominal? Seguimiento a 3 años

A single-center retrospective analysis was conducted at the Medical University of Vienna (Austria), including 230 consecutive patients treated between 2015 and 2024. Median age was 74 years, and 21% were women. All patients underwent a pre-discharge CTA. At this initial assessment, 75% presented some type of endoleak. Patients with type I or III endoleak, or mixed endoleak, without sac growth were followed at 6 months, whereas those with type II endoleak or no endoleak were followed at 12 months. Reintervention was indicated in the presence of sac growth >5 mm at 6 months or >10 mm at 12 months.

The primary endpoint was spontaneous resolution of the endoleak. Secondary endpoints included associated clinical and morphological factors, as well as changes in aneurysm sac volume.

Read also: Is it safe to use negative chronotropic drugs early after TAVI?

Endoleaks after F/B-EVAR: when CTA surveillance is a safe option

Among the 172 patients with endoleak at discharge, distribution was as follows: type I 3% (n=5), type II 34% (n=59), type III 19% (n=33), and mixed endoleak 44% (n=75). Type I endoleaks did not show spontaneous resolution. In contrast, type III endoleaks demonstrated a high resolution rate: 25% at 3 months, 39% at 6 months, 52% at 12 months, and 83% at 24 months, with no sac ruptures during follow-up. Mixed endoleaks showed a lower resolution rate (28% at 24 months), although the type II/III combination achieved a 50% resolution rate at 12 months.

Volumetric analysis identified a cutoff of 9.37 mL to define “small” and “large” endoleaks. Both groups showed similar resolution rates at 12 months (44% vs. 36%); however, at 24 months, small endoleaks resolved more frequently (72% vs. 48%). Overall, 19 patients experienced significant sac growth and were evaluated for reintervention. In multivariate analysis, three predictors were associated with a higher likelihood of spontaneous resolution: smaller maximum aortic diameter (OR 0.96; p=0.011), reduction in aneurysm sac size (OR 9.7; p<0.001), and a history of peripheral arterial disease (OR 3.6; p=0.007).

Read also: Transapical TMVR in High Risk Patients: Intrepid 5-Year Outcomes.

Conclusions: structured CTA surveillance after complex EVAR

In conclusion, in patients undergoing F/B-EVAR with type III or mixed type II/III endoleak and no sac growth on pre-discharge CTA, a CTA-based surveillance strategy—rather than immediate reintervention—proved to be safe. An 83% spontaneous resolution rate of type III endoleaks at 24 months, absence of ruptures, and a limited need for reintervention (≈8%) were observed. These findings support a strictly protocolized conservative approach in carefully selected patients.

Original Title: CTA Surveillance for Conservative Endoleak Treatment following Complex Endovascular Aneurysm Repair.

Reference: Lukas Fuchs, Anna Sotir, Johannes Klopf, Daria Anokhina, Lina El-Kilany, Florian Wolf, Christoph Neumayer, Wolf Eilenberg. Journal of Vascular Surgery.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

A New Asymptomatic Carotid Stenosis Paradigm? CREST-2 Trial Unified Results

Severe asymptomatic carotid stenosis continues to be controversial seeing the optimization of intensive medical therapy (IMT) and the availability lower periprocedural risk revascularization techniques....

Impact of Baseline Systolic Blood Pressure on Blood Pressure Changes Following Renal Denervation

Renal denervation (RDN) is a guideline-recommended therapy to reduce blood pressure in patients with uncontrolled hypertension, although uncertainties remain regarding which factors best predict...

Hypertriglyceridemia as Key Factor to Abdominal Aortic Aneurysm Development and Rupture: Genetic and Experimental Evidence

Abdominal aortic aneurysm (AAA) is a deadly vascular disease with no effective drug treatment, and risk of rupture reaching up to 80%. Even though...

Atrial Fibrillation and Chronic Kidney Disease: Outcomes of Different Stroke Prevention Strategies

Atrial fibrillation (AF) affects approximately 1 in every 4 patients with end-stage renal disease (ESRD). This population carries a high burden of comorbidities and...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Is it safe to use negative chronotropic drugs early after TAVI?

TAVI is associated with a relevant incidence of conduction system disturbances and the development of atrioventricular block that may require permanent pacemaker implantation. Many...

Long-Term Cardiovascular Risk in Patients With ANOCA: A Clinical Reality to Consider?

Chronic stable angina (CSA) remains one of the most frequent reasons for referral to diagnostic coronary angiography (CAG). In a substantial proportion of these...

Perforation Management in Bifurcations: Bench Testing of Bailout with Covered Stents

Coronary perforations during PCI are one of the most dreaded complications in interventional cardiology, especially in bifurcations. Though rate, this critical situation requires an...